BioPharma Resources

Drug Trial Radar · NCT06282575

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Jul 19, 2024

Primary completion

Dec 1, 2028

Study completion Apr 1, 2030

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.

Conditions

  • Biliary Tract Cancer

Interventions

  • ZanidatamabDrug

    Administered intravenously (IV)

  • CisplatinDrug

    Administered intravenously (IV)

  • GemcitabineDrug

    Administered intravenously (IV)

  • PembrolizumabDrug

    Administered intravenously (IV)

  • DurvalumabDrug

    Administered intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumorsTime frame: Up to 52 months

Locations

185 sites in 25 countries. Site status is shown where the registry gives one.

  • City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado · Withdrawn

  • AdventHealth Hematology and Oncology

    Orlando, Florida · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • The University of Kansas Cancer Center - Westwood

    Westwood, Kansas · Withdrawn

  • Norton Cancer Institute - Audubon

    Louisville, Kentucky · Withdrawn

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Withdrawn

  • Tufts Medical Center

    Boston, Massachusetts · Withdrawn

  • University of Michigan Hospital

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Withdrawn

  • Minnesota Oncology Hematology, P.A.

    Maple Grove, Minnesota · Withdrawn

  • Atlantic Health System/Morristown Medical Center

    Morristown, New Jersey · Withdrawn

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Centers

    New York, New York · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Saint Francis Cancer Center

    Greenville, South Carolina · Withdrawn

  • SCRI Oncology Partners

    Nashville, Tennessee · Withdrawn

  • Texas Oncology - DFW

    Dallas, Texas · Withdrawn

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The Univerrsity of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Commonwealth University, VCU Health

    Richmond, Virginia · Recruiting

  • Centro Médico Privado CEMAIC

    Córdoba, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Ciudad Autónoma de Buenos Aires (caba), Buenos Altes, Argentina · Recruiting

  • Fundación ARS Médica

    San Salvador de Jujuy, Jujuy Province, Argentina · Recruiting

  • Centro de Investigaciónes Clínicas - Clínica Viedma

    Viedma, Río Negro Province, Argentina · Recruiting

  • Hospital Provincial Del Centenario

    Rosario, Santa Fe Province, Argentina · Completed

  • Instituto Médico de la Fundación Estudios Clínicos

    Rosario, Santa Fe Province, Argentina · Recruiting

  • CAIPO Centro para la Atención Integral del Paciente Oncológico

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Centro Médico en Oncología Clínica EXELSUS S.R.L

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Imelda VZW

    Bonheiden, Antwerpen, Belgium · Withdrawn

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium · Withdrawn

  • UZ Leuven

    Leuven, Vlaams-Brabant, Belgium · Withdrawn

  • Hospital Nossa Senhora Da Conceição/Centro Integrado de Pesquisa em Oncologia CIPO-GHC

    Porto Alegre, Brazil · Recruiting

  • Instituto Nacional de Cancer - INCA

    Rio de Janeiro, Brazil · Recruiting

  • Liga Norte Riograndense Contra O Cancer

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre - HCPA

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre - ISCMPA

    Porto Alegrev, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Pio XII Hospital de Amor de Barretos

    Barretos, São Paulo, Brazil · Recruiting

  • Fundação Doutor Amaral Carvalho - Hospital Amaral Carvalho

    Jaú, São Paulo, Brazil · Active not recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto (FUNFARME)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.